The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

Editorial summary Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Genome medicine Ročník 11; číslo 1; s. 43 - 3
Hlavní autori:	Sabio, Erich, Chan, Timothy A.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 24.07.2019 BioMed Central Ltd BMC
Predmet:	Antigen Antigens Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Bioinformatics Biomarkers, Tumor - antagonists & inhibitors Biomedical and Life Sciences Biomedicine Cancer Cancer patients Cancer Research Comment Disease Progression Gene mutation Genetic aspects Human Genetics Humans Hyperprogression Immune checkpoint Immunomodulation - drug effects Immunomodulation - genetics Medicine/Public Health Metabolomics Molecular Targeted Therapy Mutation Neoplasms - drug therapy Neoplasms - etiology Neoplasms - pathology Risk Factors Systems Biology T cells T-Lymphocyte Subsets - drug effects T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism Treatment Outcome Tumor immune microenvironment and immunotherapy Tumors Antigen Immune checkpoint Mutation Hyperprogression T cells Cancer
ISSN:	1756-994X, 1756-994X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!